The Future of Drug Trials - Interview

Posted:

September 2006

BBC journalist Graham Easton investigates the future of drug trials following the events of trial TGN1412.The BBC interviewer talks to Professor Gordon Duff (Commission on Human Medicines), Professor Andre Mclean (Imperial College London), Dr Jörg Täubel (Richmond Pharmacology), Professor Terry Hamblin (University of Southampton), Dr Ganesh Suntharalingam (Northwick Park Hospital), Professor Deborah Saltman (BioMedical Central), Dr Elaine Godfrey (MHRA), and Dr Mark Lewis (Strategic Health Authority), to get their opinion leading analysis of the event and the future of drug trials, covering:

What can be learnt and changed from the incident?
Should all first in man trials be conducted in a Hospital setting?
Regulatory issues

Click here to read the transcript

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021

Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.

View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses.

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021

Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.